Skip to main content
. 2017 Apr 7;8(24):38193–38213. doi: 10.18632/oncotarget.16942

Figure 2. Anti-angiogenic therapy of orthotopic colorectal tumors promotes hypoxia-mediated, HGF-dependent MET activation.

Figure 2

A. Tumor hypoxia in HCT-116 and HT-29 tumors was determined by IHC using hypoxiprobe and anti-carbonic anhydrase IX (CAIX) antibodies. B. MET expression in HCT-116 and HT-29 tumors was determined by IHC analysis using anti-human MET antibodies. C. MET activation in HCT-116 and HT-29 tumors was determined by IHC analysis using anti-phospho MET antibodies. See Suppl. Figure S2 for representative images and score system description. Values represent mean ± SEM. Statistical significance was calculated using a Student's T-test (n = 7).